Search Thermo Fisher Scientific
GPR105 has been reported to be expressed in brain. ESTs have been isolated from kidney, placenta, uterus, and heart/melanocyte/uterus libraries. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
A330108O13Rik; BPR105; G protein coupled receptor for UDP-glucose; G protein-coupled receptor 105; G protein-coupled receptor VTR 15-20; GPCR105; Gpr105; G-protein coupled receptor 105; KIAA0001; P2ry14; P2Y purinoceptor 14; P2Y(14) receptor; P2Y14; P2Y14 receptor; purinergic receptor P2Y, G-protein coupled, 14; purinergic receptor P2Y14; UDP-glucose receptor; VTR 15-20; VTR 15-20 receptor
50 µg
100 µL
100 µL
25 µg
25 µg
100 µL
50 µg
100 µL
50 µg